The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis

Background. The recommended therapy for patients with chronic hepatitis C (CHC), genotype 1, who have cirrhosis and have failed prior therapy is 12 weeks of sofosbuvir (SOF), ledipasvir (LDV), and ribavirin (RBV). This recommendation is based on expert opinion, and the efficacy of 12 weeks of SOF/LD...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Can J Gastroenterol Hepatol
Главные авторы: Stokes, William, Fenton, Carol, Clement, Fiona, James, Matthew, Ronksley, Paul, Tang, Karen L.
Формат: Artigo
Язык:Inglês
Опубликовано: Hindawi 2017
Предметы:
Review Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5358456/
https://ncbi.nlm.nih.gov/pubmed/28367429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/6468309
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы